On June 18, Gelon Biotechnology-B (02197.HK) announced that in Phase I clinical trials evaluating the SCB-1019 bivalent RSV PreF-trimer subunit candidate vaccine developed based on Gelon Biotechnology's unique Trimer-Tag (protein trimerization) vaccine technology platform, positive preliminary immunogenicity and safety data were obtained in the elderly group. These preliminary data obtained in the elderly group (aged 60-85) are consistent with the positive data obtained in April this year in the young adult group (aged 18-59) announced by the company.
三叶草生物-B(02197.HK)公布二价RSV候选疫苗SCB-1019I期临床试验老年人群组获得积极初步数据
Adidas Bio-Tech (02197.HK) announced positive preliminary data from Phase I clinical trials of its bivalent RSV candidate vaccine SCB-1019 in elderly groups.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.